Dihydroartemisinin enhances gefitinib cytotoxicity against lung adenocarcinoma cells by inducing ROS ‐dependent apoptosis and ferroptosis
The Kaohsiung Journal of Medical Sciences · 2023-07 · 39 (7) · 699-709
DOI: 10.1002/kjm2.12684 ↗Kurz gefasst
Fachartikel in der Zeitschrift The Kaohsiung Journal of Medical Sciences, online erschienen am 14.04.2023. Verfasst von Xiang-Yu Lai und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy, Chongqing University Cancer Hospital, Chongqing, China. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Ferroptosis, Adenocarcinoma of Lung. Die Arbeit wurde bisher 30-mal zitiert (Crossref) und nennt 40 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: The Joint Research Project of Science and Health Committee of Chongqing.
Abstract (Originalsprache)
The application of epidermal growth factor receptor tyrosine kinase inhibitors (EGFR‐TKIs), such as gefitinib, has shifted lung cancer treatment from empirical chemotherapy to targeted molecular therapy. However, acquired drug resistance is inevitable in almost all non‐small cell lung cancer (NSCLC) patients treated with gefitinib. Combined treatment with dihydroartemisinin (DHA) and gefitinib produced a better inhibitory effect on lung adenocarcinoma than gefitinib treatment alone; however, the specific mechanism remains unclear. In this study, we aimed to assess the underlying mechanism of this combination treatment. We prepared gefitinib‐resistant A549 cells and investigated whether apoptosis and ferroptosis were involved in the sensitizing effect of DHA. Treatment with 5 μM gefitinib resulted in rupturing and floatation of A549 cells in the medium, while A549‐GR cells were found to be insusceptible to gefitinib. However, treatment with DHA substantially inhibited the proliferation of A549‐GR cells in a dose‐dependent manner accompanied by increased apoptosis and ferroptosis. The accumulated reactive oxygen species (ROS) was crucial for the inhibitory effect of DHA on A549‐GR cells. Moreover, cellular autophagy was significantly upregulated post‐DHA treatment. The combined treatment of DHA and gefitinib resulted in inhibition of proliferation of A549, H1975, and HCC827 cells, and ROS accumulation and a remarkable induction of apoptosis was observed in A549‐GR cells. DHA significantly induced apoptosis and ferroptosis in a dose‐dependent manner and exhibited high cellular toxicity on A549‐GR cells when combined with gefitinib.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmacy, Chongqing University Cancer Hospital, Chongqing, China.
- Department of Medical Oncology, Chongqing University Cancer Hospital, Chongqing, China.
- Department of Critical Care Medicine, Chongqing University Cancer Hospital, Chongqing, China.
ORCID-Profile: Ming-Ming Zhou
Förderung
- The Joint Research Project of Science and Health Committee of Chongqing
Zitieren
APA
Lai, X. Y., Shi, Y. M., & Zhou, M. M. (2023). Dihydroartemisinin enhances gefitinib cytotoxicity against lung adenocarcinoma cells by inducing ROS ‐dependent apoptosis and ferroptosis. The Kaohsiung Journal of Medical Sciences, 39(7), 699-709. https://doi.org/10.1002/kjm2.12684
Vancouver
Lai XY, Shi YM, Zhou MM. Dihydroartemisinin enhances gefitinib cytotoxicity against lung adenocarcinoma cells by inducing ROS ‐dependent apoptosis and ferroptosis. The Kaohsiung Journal of Medical Sciences. 2023;39(7):699-709. doi:10.1002/kjm2.12684
BibTeX
@article{Lai2023,
author = {Lai, Xiang-Yu and Shi, Yu-Mei and Zhou, Ming-Ming},
title = {Dihydroartemisinin enhances gefitinib cytotoxicity against lung adenocarcinoma cells by inducing ROS ‐dependent apoptosis and ferroptosis},
journal = {The Kaohsiung Journal of Medical Sciences},
year = {2023},
volume = {39},
number = {7},
pages = {699--709},
doi = {10.1002/kjm2.12684}
}
EUVIMED